Astellas Pharma Announces New Board Slate and Governance Changes for 2026

The latest announcement is out from Astellas Pharma ( (JP:4503) ).

Astellas Pharma has proposed a slate of director nominees, including the reappointment of Representative Directors Kenji Yasukawa as chairman, Naoki Okamura as president and CEO, and Katsuyoshi Sugita as executive vice president and chief people officer. Several outside directors, such as Masahiro Miyazaki, Yoichi Ohno, Andreas Busch and Mark Enyedy, are also nominated for reelection, alongside the continuation of audit and supervisory committee member Rika Hirota.

The company plans to add outside director Shigeki Takahara as a new audit and supervisory committee member while three current outside directors, including audit and supervisory committee member Mika Nakayama, will retire. Subject to shareholder approval in June 2026, the reshaped board will maintain a strong presence of outside directors and specialized audit and supervisory members, underscoring Astellas’s focus on governance continuity and oversight as it navigates its strategic and operational priorities.

The most recent analyst rating on (JP:4503) stock is a Buy with a Yen2800.00 price target. To see the full list of analyst forecasts on Astellas Pharma stock, see the JP:4503 Stock Forecast page.

More about Astellas Pharma

Astellas Pharma Inc., listed on the Tokyo Stock Exchange, is a global pharmaceutical company focused on developing, manufacturing and marketing prescription medicines. The company concentrates on innovative therapies across key disease areas, leveraging both internal R&D and external partnerships to strengthen its position in the competitive biopharmaceutical industry.

YTD Price Performance: 19.71%

Average Trading Volume: 6,690,885

Technical Sentiment Signal: Buy

Current Market Cap: Yen4444.3B

See more insights into 4503 stock on TipRanks’ Stock Analysis page.